Ani Pharmaceuticals, Inc. · NASDAQ:ANIP
Ani Pharmaceuticals — Investor Presentation (November 2014)
19 slides from Ani Pharmaceuticals's investor presentation, Nov 10, 2014
Slide 1: Corporate Presentation November 2014
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation November 2014
Slide 2: Forward-Looking Statements
2 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, stat
Slide 3: ANI Mission Statement
3 3 ANI Mission Statement ANI Pharmaceuticals is an integrated specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals. ANI’s mission is to develop, manufacture, and market niche generic pharmaceuticals, focusing on opportunities in p
Slide 4: ANI Overview – Poised for Growth
4 ANI Overview – Poised for Growth ANI Today ▪ Experienced management team ▪ Current business – For the nine months ended September 30, 2014: $34.9 million total net revenues □ $29.2 million ANI Rx product revenues □ $5.7 million c ontract manufacturing/services revenues □ Growth of 79% year/year ▪
Slide 5: ANI Recent History and Highlights
5 5 ANI Recent History and Highlights 2009 New executive management team: Art Przybyl, CEO and Charlotte Arnold, CFO 2010 Management implements strategy to expand ANI labeled Rx products 2011 ANI expands marketed Rx portfolio to seven products through internal development and acquisition 2013 ANI co
Slide 6: Sales and Marketing / Financial Overview
6 6 Sales and Marketing / Financial Overview
Slide 7: ANI Historical Revenue Growth
7 ANI Historical Revenue Growth 7 $s in millions 39% C ost of sales as a percentage of net revenues, excluding depreciation and amortization 42% 43% 33% 22%
Slide 8: ANI Current Rx Product Portfolio
8 ANI Current Rx Product Portfolio Generic Products Position Market Share (1) EE/MT Tablets #1 42% Fluvoxamine Tablets #1 56% HC Enema #1 85% Metoclopramide Solution #2 31% Opium Tincture #1 78% Methazolamide Tablets Launched November 2014 8 Branded Products Lithobid ® Vancocin ® C ortenema ® Reglan
Slide 9: ANI Contract Manufacturing Revenues
9 ANI Contract Manufacturing Revenues 9 Current Business ▪ $5.7 million in contract manufacturing and services revenues during the nine - month period ended September 30, 2014 ▪ Four customers – Eight products and nineteen SKUs Future Opportunities ▪ Potential future royalty: Teva’s testosterone gel
Slide 10: ANI Financial Highlights
10 ANI Financial Highlights 10 YTD Results – 2014 ($ in millions) Nine months ended Sept 30, 2014 Sept 30, 2013 % Growth Net revenues $34.9 $19.6 79% Adjusted non - GAAP EBITDA (1) $14.5 $3.6 306% (1) Please see pages 18 and 19 for US GAAP reconciliations (2) November 3, 2014 press release Fourth Qu
Slide 11: Product Development / Business Development Overview
11 11 Product Development / Business Development Overview
Slide 12: ANI Product Development Pipeline
12 12 ANI Product Development Pipeline Development Pipeline: 48 p roducts in development ▪ Nine filed products – One ANDA granted expedited review – Development collaborations: Ricon, Sofgen, Sterling ▪ Total combined current market: $2.7 billion (1) (1) Based on Company estimates, and recent IMS an
Slide 13: ANI Business Development Highlights
13 13 ANI Business Development Highlights Acquired Vancocin® and related assets from Shire, August 2014 Acquired Lithobid® from Noven, July 2014 Acquired 31 generic products from Teva, December 2013 Product development partnership with Sofgen, August 2013; expanded, April 2014 Acquired royalty arran
Slide 14: Manufacturing Overview
14 14 Manufacturing Overview
Slide 15: ANI Manufacturing – Main Street Facility
15 15 ANI Manufacturing – Main Street Facility Location: Baudette , Minnesota ▪ 52,000 square feet of manufacturing , packaging, and warehouse facilities ▪ Rx solutions , suspensions , topicals , tablets , and capsules ▪ DEA - licensed for Schedule II controlled substances ▪ 17,000 square feet of la
Slide 16: ANI Manufacturing – IDC Road Facility
16 16 ANI Manufacturing – IDC Road Facility Location: Baudette, Minnesota ▪ Fully - contained h igh potency facility with capabilities to manufacture h ormone , steroid , and oncolytic products ▪ 47,000 square feet of manufacturing and packaging, and warehouse facilities ▪ 100 nano - gram per eight
Slide 17: ANI Summary
17 ANI Summary ANI is an integrated specialty generic pharmaceutical firm with: ▪ Profitable base business generating organic growth – Fourth quarter 2014 guidance (1) □ Net revenues of $17 million to $18 million □ Adjusted non - GAAP EBITDA of $9.75 million to $10.25 million □ Adjusted non - GAAP E
Slide 18: U.S. GAAP Reconciliations
18 U.S. GAAP Reconciliations 18 2014 2013 2014 2013 Operating (Loss)/Income $8,199 $810 $9,234 ($2,562) Add back Depreciation and amortization 1,187 382 2,596 673 Add back Stock-based compensation 692 3 2,719 3 Merger-related expenses, not already added back Adjusted EBITDA $10,078 $1,696 $14,549 $3
Slide 19: U.S. GAAP Reconciliations
19 U.S. GAAP Reconciliations 19 Three months ended September 30, 2014 Net Income 6,746 Add back Stock-based compensation 692 Adjusted Net Income Used in Calculating Adjusted non-GAAP Diluted Earnings Per Share 7,438$ Diluted Weighted-Average Shares Outstanding 11,302 Adjusted non-GAAP Diluted Earnin
ANI Pharmaceuticals — Investor Presentation (November 2014) on 6ix